Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANI PHARMACEUTICALS INCANIP · Entity 4638 | Director | May 21, 2026 | June 11, 2026 |
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Director | June 11, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANI PHARMACEUTICALS INC
Report date May 21, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,514 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 4,357 · Balance 29,514 F1: Represents a restricted stock award that will vest in full on May 21, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock award that will vest in full on May 21, 2027.
Cardiff Oncology, Inc.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2036-06-11 | Direct | 209,331 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 40,565 · Balance 209,331 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ZOGENIX, INC.
Report date March 07, 2022 · Filed March 09, 2022
Section 16 reporting ended · disclosed 2022-03-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-03-07 transaction · row 1
1 source rowRow 1 · 2022-03-07 · Other · Disposed 32,567 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 18, 2022, (the "Merger Agreement"), among UCB S.A., a societe anonyme formed under the laws of Belgium ("Parent"), Zinc Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Purchaser") and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 7, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $26.00 in cash (the "Cash Amount") plus a contingent value right ("CVR"), which CVR represents the right to receive a contingent payment of $2.00 which amount will become payable, if at all, if a specified milestone is achieved on or prior to December 31, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.80 · Expires 2025-06-17 | Direct | 0 |
Reported balance
After 2022-03-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-07 · Disposition to issuer · Disposed 3,000 · Balance 0 F2: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") with an exercise price less than $26.00 (each, an "In the Money Option"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an "Out of the Money Option"), F3: (Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.83 · Expires 2031-05-26 | Direct | 0 |
Reported balance
After 2022-03-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-07 · Disposition to issuer · Disposed 22,000 · Balance 0 F2: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") with an exercise price less than $26.00 (each, an "In the Money Option"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an "Out of the Money Option"), F3: (Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 18, 2022, (the "Merger Agreement"), among UCB S.A., a societe anonyme formed under the laws of Belgium ("Parent"), Zinc Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Purchaser") and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 7, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $26.00 in cash (the "Cash Amount") plus a contingent value right ("CVR"), which CVR represents the right to receive a contingent payment of $2.00 which amount will become payable, if at all, if a specified milestone is achieved on or prior to December 31, 2023.
F2: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") with an exercise price less than $26.00 (each, an "In the Money Option"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an "Out of the Money Option"),
F3: (Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 16, 2026 01:30 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 40,565 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001543174-26-000005 · ownership.xml · derivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,331 Underlying: Common Stock · 40,565 shares Expires 2036-06-11 Read SEC document |
| May 21, 2026 Filed Jun 11, 2026 01:09 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 4,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001543174-26-000003 · wk-form4_1781140154.xml · nonDerivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,514 F1 · kind: Represents a restricted stock award that will vest in full on May 21, 2027. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 23:09 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 1,800 | $81.15 | $146,070.00 |
DisclosureSEC source: 0001543174-25-000006 · wk-form4_1765321783.xml · nonDerivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,157 F1 · price: The shares were sold in multiple trades at prices ranging from $81.14 to $81.16. The price reported above reflects the weighted average sales price. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 13:39 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 40,565 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001641172-25-017072 · ownership.xml · derivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,766 Underlying: Common Stock · 40,565 shares Expires 2035-06-26 Read SEC document |
| May 22, 2025 Filed May 27, 2025 22:17 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 4,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001543174-25-000002 · wk-form4_1748384233.xml · nonDerivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,957 F1 · kind: Represents a restricted stock award that will vest in full on May 22, 2026. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 22:00 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 10,000 | $3.42 | $34,224.00 |
DisclosureSEC source: 0000950170-24-136725 · ownership.xml · nonDerivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 20:09 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 29,700 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001628280-24-030642 · wk-form4_1719864555.xml · derivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,201 Underlying: Common Stock · 29,700 shares Expires 2034-06-27 Read SEC document |
| May 21, 2024 Filed May 23, 2024 23:59 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 4,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001543174-24-000005 · wk-form4_1716508769.xml · nonDerivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,621 F1 · kind: Represents a restricted stock award that will vest in full on May 21, 2025. Read SEC document |
| May 16, 2024 Filed May 17, 2024 22:01 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 2,000 | $63.87 | $127,740.00 |
DisclosureSEC source: 0001543174-24-000002 · wk-form4_1715983230.xml · nonDerivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,211 Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:02 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 27,700 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001628280-23-022731 · wk-form4_1687294950.xml · derivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,501 Underlying: Common Stock · 27,700 shares Expires 2033-06-15 Read SEC document |
| May 23, 2023 Filed May 24, 2023 20:36 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 6,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-064160 · tm2316872-6_4seq1.xml · nonDerivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,211 F1 · kind: Represents a restricted stock award that will vest in full on May 23, 2024. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 12:37 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 3,600 | $1.72 | $6,192.00 |
DisclosureSEC source: 0001628280-22-025101 · wf-form4_166359105093640.xml · nonDerivative · entry 2 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 12:37 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 6,400 | $1.72 | $10,976.00 |
DisclosureSEC source: 0001628280-22-025101 · wf-form4_166359105093640.xml · nonDerivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,400 Read SEC document |
| March 19, 2022 Filed Mar 22, 2022 21:36 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 13,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003266 · form4-03222022_020316.xml · nonDerivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,346 F1 · kind: Represents a restricted stock award that will vest in three equal annual installments on the first, second and third anniversaries of March 19, 2022. Read SEC document |
| March 09, 2022 Filed Mar 10, 2022 23:43 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 26,800 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001628280-22-005796 · wf-form4_164695577272689.xml · derivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,801 Underlying: Common Stock · 26,800 shares Expires 2032-03-09 Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 19:11 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 22,000 | Not disclosed Strike: $17.83 | Not disclosed |
DisclosureSEC source: 0000899243-22-010303 · doc4.xml · derivative · entry 3 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,000 shares Expires 2031-05-26 F2 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") with an exercise price less than $26.00 (each, an "In the Money Option"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an "Out of the Money Option"), F3 · price: (Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration. F2 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") with an exercise price less than $26.00 (each, an "In the Money Option"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an "Out of the Money Option"), F3 · derivative.exercise_date: (Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 19:11 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,000 | Not disclosed Strike: $12.80 | Not disclosed |
DisclosureSEC source: 0000899243-22-010303 · doc4.xml · derivative · entry 2 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2025-06-17 F2 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") with an exercise price less than $26.00 (each, an "In the Money Option"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an "Out of the Money Option"), F3 · price: (Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration. F2 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") with an exercise price less than $26.00 (each, an "In the Money Option"), was canceled and converted into the right to receive an amount in cash equal to, subject to applicable tax withholding, the product of (i) the excess, if any of the Cash Amount over the exercise price per Share underlying such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Options and one CVR; (b) each Company Option with an exercise price equal to or greater than $26.00 but less than $28.00 (each, an "Out of the Money Option"), F3 · derivative.exercise_date: (Continued from Footnote 2) was canceled and converted into the right to receive, subject to the terms of the Merger Agreement, if and when (and only if and when) payments in respect of CVRs are required to be made, $28.00 in cash (less the applicable exercise price per Share subject to such Out of the Money Option); (c) each Company Option with an exercise price equal to or greater than $28.00, was canceled for no consideration. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 19:11 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | OtherCommon Stock | 32,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-010303 · doc4.xml · nonDerivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 18, 2022, (the "Merger Agreement"), among UCB S.A., a societe anonyme formed under the laws of Belgium ("Parent"), Zinc Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Purchaser") and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 7, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $26.00 in cash (the "Cash Amount") plus a contingent value right ("CVR"), which CVR represents the right to receive a contingent payment of $2.00 which amount will become payable, if at all, if a specified milestone is achieved on or prior to December 31, 2023. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 18, 2022, (the "Merger Agreement"), among UCB S.A., a societe anonyme formed under the laws of Belgium ("Parent"), Zinc Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Purchaser") and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 7, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $26.00 in cash (the "Cash Amount") plus a contingent value right ("CVR"), which CVR represents the right to receive a contingent payment of $2.00 which amount will become payable, if at all, if a specified milestone is achieved on or prior to December 31, 2023. Read SEC document |
| November 29, 2021 Filed Nov 30, 2021 21:55 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | SaleCommon Stock | 5,305 | $11.72 | $62,174.60 |
DisclosureSEC source: 0001375151-21-000102 · wf-form4_163832730682507.xml · nonDerivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,567 Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:13 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 44,001 | $0.00 Strike: $7.98 | $0.00 |
DisclosureSEC source: 0001628280-21-012177 · wf-form4_162370159154248.xml · derivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,001 Underlying: Common Stock · 44,001 shares Expires 2031-06-10 F1 · derivative.exercise_date: 14,667 vest on 6/10/2022, 6/10/2023, and 6/20/2024 Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 19:20 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | PurchaseCommon Stock | 5,000 | $17.05 | $85,247.50 |
DisclosureSEC source: 0001375151-21-000072 · wf-form4_162276242870509.xml · nonDerivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,872 F1 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.045 to $17.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| May 27, 2021 Filed May 28, 2021 19:59 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $17.83 | $0.00 |
DisclosureSEC source: 0001375151-21-000058 · wf-form4_162224636664484.xml · derivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-05-27 F1 · derivative.exercise_date: The option was granted on May 27, 2021, the date of the Issuer's 2021 Annual Meeting of Stockholders, and shall become exercisable with respect to the underlying shares of common stock in a series of twelve (12) successive, equal monthly installments on each monthly anniversary of the grant date, such that the option shall be fully vested twelve months following the date of grant, subject to the Reporting Person's continuing service on the Board of the Issuer through such dates. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 17:05 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | SaleCommon Stock | 15,000 | $20.74 | $311,065.50 |
DisclosureSEC source: 0001375151-20-000155 · wf-form4_160573713523913.xml · nonDerivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,872 F1 · kind: This transaction was effected to satisfy certain tax obligations of the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.69 to $20.80, inclusive. The Reporting Person undertakes to provide to Zogenix, Inc., any security holder of Zogenix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2020 Filed Jun 29, 2020 21:12 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $29.13 | $0.00 |
DisclosureSEC source: 0001375151-20-000110 · wf-form4_159347950820430.xml · derivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2030-05-29 F1 · derivative.exercise_date: The option was granted on May 29, 2020, the date of the Company's 2020 Annual Meeting of Stockholders, and vests in twelve (12) equal monthly installments from the grant date, such that the option is fully vested on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service to the Company on each vesting date. Read SEC document |
| May 22, 2019 Filed May 28, 2019 16:07 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $39.02 | $0.00 |
DisclosureSEC source: 0001375151-19-000081 · wf-form4_155907401375516.xml · derivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-05-22 F1 · derivative.exercise_date: The option was granted on May 22, 2019, the date of the Company's 2019 Annual Meeting of Stockholders, and vests in twelve (12) equal monthly installments from the grant date, such that the option is fully vested on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service to the Company on each vesting date. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:48 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001375151-19-000024 · wf-form4_155208168912225.xml · derivative · entry 9 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2027-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on May 23, 2017, the date of the Company's Annual Meeting of Stockholders, and vests in a series of twelve (12) successive, equal monthly installments measured from the date of grant, subject to the Reporting Person's continued service to the Company on each vesting date. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:48 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001375151-19-000024 · wf-form4_155208168912225.xml · derivative · entry 8 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on July 13, 2016 and vests in a series of twelve (12) successive, equal monthly installments, on the first day of each calendar month following the date of grant, subject to the Reporting Person's continued service to the Company on each vesting date. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:48 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $12.80 | $0.00 |
DisclosureSEC source: 0001375151-19-000024 · wf-form4_155208168912225.xml · derivative · entry 7 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 6,000 shares Expires 2025-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on June 18, 2015 and vests in a series of twelve (12) successive, equal monthly installments measured from the date of grant, subject to the Reporting Person's continued service to the Company on each vesting date. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:48 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,375 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001375151-19-000024 · wf-form4_155208168912225.xml · derivative · entry 6 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,375 shares Expires 2025-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on February 6, 2015, which is the vesting commencement date. Shares subject to the option vests over three years in thirty-six equal monthly installments, subject to the Reporting Person's continued service to the Company on each vesting date. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:48 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | SaleCommon Stock | 17,503 | $50.65 | $886,474.44 |
DisclosureSEC source: 0001375151-19-000024 · wf-form4_155208168912225.xml · nonDerivative · entry 5 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,872 F1 · price: The price reported in Column 4 is a weighted average price.These shares were sold in multiple transactions at prices ranging from $50.40 to $50.90, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:48 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | Exercise / conversionCommon Stock | 20,000 | $8.99 | $179,800.00 |
DisclosureSEC source: 0001375151-19-000024 · wf-form4_155208168912225.xml · nonDerivative · entry 4 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:48 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | Exercise / conversionCommon Stock | 20,000 | $12.75 | $255,000.00 |
DisclosureSEC source: 0001375151-19-000024 · wf-form4_155208168912225.xml · nonDerivative · entry 3 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:48 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | Exercise / conversionCommon Stock | 6,000 | $12.80 | $76,800.00 |
DisclosureSEC source: 0001375151-19-000024 · wf-form4_155208168912225.xml · nonDerivative · entry 2 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:48 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | Exercise / conversionCommon Stock | 9,375 | $10.40 | $97,500.00 |
DisclosureSEC source: 0001375151-19-000024 · wf-form4_155208168912225.xml · nonDerivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2018 Filed May 24, 2018 18:36 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $41.68 | $0.00 |
DisclosureSEC source: 0001375151-18-000047 · wf-form4_152720139166432.xml · derivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-22 F1 · kind: Annual director stock option grant under the issuer's incentive compensation plan. F2 · derivative.exercise_date: The option was granted on May 23, 2018, the date of the Company's Annual Meeting of Stockholders, and vests in twelve (12) equal monthly installments from the grant date such that the option is fully vested on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Company on each vesting date. Read SEC document |
| May 23, 2017 Filed May 23, 2017 19:03 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001375151-17-000039 · wf-form4_149558058929011.xml · derivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-22 F1 · kind: Annual director stock option grant under the issuer's incentive compensation plan. F2 · derivative.exercise_date: The option was granted on May 23, 2017, the date of the Company's Annual Meeting of Stockholders, and vests in a series of twelve (12) successive, equal monthly installments beginning on June 23, 2017, subject to the reporting person's continued service to the Company on each vesting date. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 18:25 UTC | ZOGENIX, INC. ZGNX · Entity 129305 | PurchaseCommon Stock | 5,000 | $11.00 | $55,000.00 |
DisclosureSEC source: 0000899243-17-008223 · doc4.xml · nonDerivative · entry 1 TANNENBAUM RENEE P · CIK 0001543174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.